ERJ open research · 2026
Improvements in small airway dysfunction and respiratory symptoms following tezepelumab for severe asthma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kupershmidt Aviv, Elkayam Gal, Urtreger Nimrod, Malloul Ariel, Regev-Friedman Inbal, Unterman Avraham, Amor Shai Moshe, Enghelberg Sharon, Freund Ophir, Bar-Shai Amir
Аннотация
BACKGROUND: Small airway dysfunction (SAD) is a key feature of severe asthma, contributing to poor symptom control and exacerbations. Tezepelumab has demonstrated efficacy in reducing exacerbations and improving lung function, but its specific effects on SAD remain underexplored. We aimed to assess changes in SAD among patients initiating tezepelumab.
METHODS: A prospective observational study was carried out among patients with severe asthma treated with tezepelumab in a tertiary centre. SAD was assessed at baseline and 6 months using impulse oscillometry (IOS) and spirometry. We focused on frequency dependence of resistance (R 5-20) and the area under the reactance curve (AX) to define SAD, with pathological cut-offs >0.1 kPa·L-1·s-1 and >1.0 kPa·L-1, respectively. Paired analyses were used to compare changes over time.
RESULTS: 34 patients were included (median age 60 years, 74% females, 21% biologic-experienced) with a median follow-up of 183 days. There were significant improvements from baseline to follow-up in forced expiratory volume in 1 s (FEV1) (median 1.73 versus 1.97 L, p=0.001), mid-expiratory flow at 25-75% of forced vital capacity (FVC) (median 1.26 versus 1.73 L·s-1, p=0.002), R 5-20 (median 0.16 versus 0.08 kPa·L-1·s-1, p<0.001) and AX (median 1.62 versus 0.80 kPa·L-1, p<0.001). Improvements in IOS parameters were larger in patients with increased Asthma Control Test (ACT) scores ≥3 points. Prevalence of SAD decreased from 76% to 44% at follow-up (p=0.003). SAD at follow-up was associated with smoking, lower FEV1 and FVC, and smaller improvements in ACT score.
CONCLUSION: Tezepelumab significantly improved small airway function, which was associated with better asthma control. Our findings highlight SAD as a treatable trait in patients with severe asthma.
METHODS: A prospective observational study was carried out among patients with severe asthma treated with tezepelumab in a tertiary centre. SAD was assessed at baseline and 6 months using impulse oscillometry (IOS) and spirometry. We focused on frequency dependence of resistance (R 5-20) and the area under the reactance curve (AX) to define SAD, with pathological cut-offs >0.1 kPa·L-1·s-1 and >1.0 kPa·L-1, respectively. Paired analyses were used to compare changes over time.
RESULTS: 34 patients were included (median age 60 years, 74% females, 21% biologic-experienced) with a median follow-up of 183 days. There were significant improvements from baseline to follow-up in forced expiratory volume in 1 s (FEV1) (median 1.73 versus 1.97 L, p=0.001), mid-expiratory flow at 25-75% of forced vital capacity (FVC) (median 1.26 versus 1.73 L·s-1, p=0.002), R 5-20 (median 0.16 versus 0.08 kPa·L-1·s-1, p<0.001) and AX (median 1.62 versus 0.80 kPa·L-1, p<0.001). Improvements in IOS parameters were larger in patients with increased Asthma Control Test (ACT) scores ≥3 points. Prevalence of SAD decreased from 76% to 44% at follow-up (p=0.003). SAD at follow-up was associated with smoking, lower FEV1 and FVC, and smaller improvements in ACT score.
CONCLUSION: Tezepelumab significantly improved small airway function, which was associated with better asthma control. Our findings highlight SAD as a treatable trait in patients with severe asthma.